RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kaleido Biosciences Stock

Kaleido Biosciences Dividend 2024

Kaleido Biosciences Dividend

0 USD

Kaleido Biosciences Dividend yield

Ticker

KLDO

ISIN

US4833471000

WKN

A2PELT

How much dividend does Kaleido Biosciences 2024 pay?

According to the latest status from October 2024, Kaleido Biosciences paid a total of 0 USD per share in dividends within the last 12 months. With the current Kaleido Biosciences price of 0 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Kaleido Biosciences Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Kaleido Biosciences Dividend Safe?

Kaleido Biosciences has been increasing the dividend for 0 years.

Over the past 6 years, Kaleido Biosciences has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Kaleido Biosciences's Dividend Distributions

Kaleido Biosciences’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Kaleido Biosciences's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Kaleido Biosciences's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Kaleido Biosciences’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Kaleido Biosciences Aktienanalyse

What does Kaleido Biosciences do?

Kaleido Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for a variety of metabolic and immune disorders. The company, based in Lexington, Massachusetts, was founded in 2015 by David Berry, Michael Fischbach, Geoff von Maltzahn, and Noubar Afeyan. The founders brought together their expertise from various fields to develop a new class of drugs based on the manipulation of the microbial ecosystem in the human gut. The company has developed an innovative business model based on the Microbiome Metabolic Therapies (MMT) platform. This platform utilizes naturally occurring, non-pathogenic microorganisms to modulate specific metabolic pathways in the human body. By manipulating the microbiome, scientists at Kaleido Biosciences can influence specific disease states and develop new therapies for metabolic and immune system disorders. One of the areas of focus for the company is the treatment of various metabolic disorders, with a particular emphasis on regulating carbohydrate metabolism. Kaleido Biosciences uses the MMT platform to modify certain bacteria in the gut. The goal is to shift the balance of the gut flora in a way that promotes or suppresses specific metabolic reactions in the body. Another important area of focus is immunotherapy. The aim is to selectively influence the body's immune system to treat various disease states. Kaleido Biosciences is working on strategies to activate bacteria in the gut and trigger specific immune responses. In recent years, the company has developed several promising products and is currently in the clinical trial phase. One product is an MMT candidate for the treatment of celiac disease, an autoimmune disorder related to gluten digestion. Another product is an MMT candidate for the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency. Kaleido Biosciences also collaborates closely with various companies and partners to further develop its technology platform and identify new products. In 2018, the company entered into a strategic collaboration agreement with Pfizer to identify and develop a range of MMT candidates for the treatment of metabolic and immune disorders. Overall, Kaleido Biosciences Inc has made remarkable progress in a short period of time and developed an innovative technology platform for the development of new therapeutics for complex disease states. The company has quickly established a solid value creation community of investors, partners, and customers. With continued research efforts, partnership endeavors, and a customer-oriented approach, the future looks bright for Kaleido Biosciences. Kaleido Biosciences is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Kaleido Biosciences stock

How much dividend does Kaleido Biosciences pay?

Over the past 12 months, Kaleido Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kaleido Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kaleido Biosciences?

The current dividend yield of Kaleido Biosciences is .

When does Kaleido Biosciences pay dividends?

Kaleido Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kaleido Biosciences?

Kaleido Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kaleido Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kaleido Biosciences located?

Kaleido Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaleido Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaleido Biosciences from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Kaleido Biosciences pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Kaleido Biosciences in the year 2023?

In the year 2023, Kaleido Biosciences distributed 0 USD as dividends.

In which currency does Kaleido Biosciences pay out the dividend?

The dividends of Kaleido Biosciences are distributed in USD.

Andere Kennzahlen von Kaleido Biosciences

Our stock analysis for Kaleido Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kaleido Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.